Member Info for Porter_

“Able to” is very different to “is”

Even if the plant does mechanically operate, the team need to confirm that they’ve sorted the water source issues. Plant is defunct without the ability to actually process minerals ☠️

Carlsberg have water for their production, Prem don’t👌🏻

Yes the pump and dumpers with no understanding of the company have gone away with their 6 pieces of silver. Now they’re gone, we’ve stabilised and can move up gracefully

Gaining traction and now showing up in global listings.

Could be seeing a fabulous Q4 in 2025 if it continues!

Yep looks like they keep holding to fill the orders.

Nice to see chunky buys going through :)

Takeaways:

- Pet pharma deal now in sight with funds expected

- Mash will now be split into 2 programmes, 1 for early stage Mash and 1 for late stage mash, doubling the prospects of commercialisation

- Papers being submitted to the European Health Agencies to commence human trials, which owing to digitalisation and AI, now have a quick turnaround for approvals

Agree Money, wouldn’t surprise me if Genflow had been approached and told we like your science, but if you want a chance of buy out, you need to perform your trials under the observation of our own approved lab partner!

Great partnership announcement with the approved lab partners for Pfizer, GSK, Nestle and Sanofi.

Means any one of those Pharma giants can procure the MASH programme without having to go through further validation.

Incredibly smart move from Genflow!

“Physiogenex provides preclinical in vivo and ex vivo CRO services with 20 years of expertise in evaluating drugs targeting metabolic disorders such as obesity, diabetes, NASH/MASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia and atherosclerosis.

We develop in-house and gold standard preclinical models in our cutting-edge facilities near Toulouse, France.”

https://www.physiogenex.com/#:~:text=Preclinical%20CRO%20for%20metabolic%20disorders,Learn%20more

Approx £1 a share Jam

AI overview -

Big Pharma's Need:

If a large pharmaceutical company is actively seeking to enter the anti-aging space, or if Genflow's technology complements their existing research pipeline, they may be willing to pay a premium.

While it's difficult to pinpoint an exact figure, based on the market capitalization of other companies in similar fields, a valuation in the range of $50 million to $500 million is possible.

For example, Solid Biosciences, a company focused on gene therapy for Duchenne muscular dystrophy, has a market cap of around $495 million. Genflow's technology, with its broader potential for rejuvenation, could potentially command a similar or even higher valuation if it reaches a similar stage of development.

It’s managed to hold, now the US markets are opening again so let’s see if they clock the volume 😁

Sanofi just announced a $1.6bn deal for a vaccination developer in Phase 1 trials for just 1 programme!

https://pharmaphorum.com/news/sanofi-buy-uk-vaccines-developer-vicebio-16bn

The potential for Genflow with their 5 programmes is massive

- 2 patents in final screening

- 5 programmes, with 3 further compound variations

- Programmes include longevity, dog health, liver disease, eye damage and muscle disease

- Samsung just inked a $10bn deal for a eye damage programme

- Eli Lilly just inked a $650m deal for a longevity programme

- Genflow have received €14m in funding with a €3.5m mcap

- The funding has included grants provided through the European Union

- Only listed Longevity Company in Europe

- CEO is ex Nasdaq, Pfizer and already has patents in his own name (strong proven track record)

Agree Swanns not the seller and was having a catch with fellow investors last night.

More likely the Bauers and Beestons who collectively had 8% between them 👌🏻

Https://m.alphabiz.co.kr/news/print.html?newsid=131073

$8.5bn deal just inked by the Samsung Group to expand their eye science

Genflow have their own eye product prepped for commercialisation

They’re still fishing for shares, whoever has the order has firm instructions

£3m mcap, despite £4m of European Union backed funding 🙈

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) confirmed that it has been awarded roughly €4 million in non-dilutive financial support from the Wallonia region of Belgium to support the development of its lead gene therapy candidate to treat metabolic-associated steatohepatitis (MASH).

That hero is Genflow with their GF-1006:

https://www.dailymail.co.uk/sciencetech/article-14915995/pfizer-covid-vaccine-eye-changes-damage-risk.html?ito=social-facebook&fbclid=IwQ0xDSwLoznRleHRuA2FlbQIxMQABHuEjjJZXzZx_1NZiyQaQV6d5KcT4Vd67Ks-CXbkAqaRVCThSVOUbZcRp4lcI_aem_fNz9jfQQlZJGQ4h4cOy1ow

At least the seller is now out and it can continue north once again